Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving hundreds of leading biopharmaceutical companies globally:

McKesson
Queensland Health
Accenture
QuintilesIMS
Daiichi Sankyo
Harvard Business School

Generated: September 23, 2019

DrugPatentWatch Database Preview

Patent: 9,505,834

  Try a free trial


See Plans and Pricing

« Back to Dashboard

Summary for Patent: 9,505,834
Title:Methods for controlling the galactosylation profile of recombinantly-expressed proteins
Abstract: The present invention relates to methods for modulating the glycosylation profile of recombinantly-expressed proteins. In particular, the present invention relates to methods of controlling the galactosylation profile of recombinantly-expressed proteins by supplementing production medium, e.g., a hydrolysate-based or a chemically defined medium, with manganese and/or D-galactose
Inventor(s): Bengea; Cornelia (Auburn, MA), Rives; Lisa M. (Natick, MA), Hossler; Patrick (Westborough, MA)
Assignee: AbbVie Inc. (North Chicago, IL)
Application Number:15/086,739
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 9,505,834
Patent Claims:see list of patent claims

Details for Patent 9,505,834

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Abbvie Inc HUMIRA adalimumab SYRINGE 125057 001 2002-12-31 ➤ Sign Up AbbVie Inc. (North Chicago, IL) 2031-04-27 RX search
Abbvie Inc HUMIRA adalimumab VIAL 125057 002 2002-12-31 ➤ Sign Up AbbVie Inc. (North Chicago, IL) 2031-04-27 RX search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving hundreds of leading biopharmaceutical companies globally:

Harvard Business School
Citi
Fish and Richardson
UBS
Deloitte
Queensland Health

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.